Verrica Pharmaceuticals INC 10-Q quarterly reports

Verrica Pharmaceuticals Inc. reported significantly increased revenue and a substantial reduction in net loss for the nine months ended September 30, 2025, driven by YCANTH sales and collaboration milestones, despite ongoing liquidity concerns.

Verrica Pharmaceuticals reports Q2 2025 results with increased collaboration revenue but acknowledges substantial doubt about its ability to continue as a going concern.

Verrica Pharmaceuticals reports Q1 2025 results, highlighting revenue growth but also raising concerns about its ability to continue as a going concern due to liquidity challenges and debt obligations.

Verrica Pharmaceuticals' Q3 2024 results reveal a net loss and concerns about its ability to continue as a going concern, despite ongoing commercialization efforts.

Verrica Pharmaceuticals reported its Q2 2024 financial results, highlighting increased revenue but also significant operating losses and concerns about its ability to continue as a going concern.

Verrica Pharmaceuticals reported a net loss of $20.3 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.